1.57
+0.09(+6.08%)
Currency In USD
| Previous Close | 1.48 |
| Open | 1.49 |
| Day High | 1.61 |
| Day Low | 1.46 |
| 52-Week High | 3.11 |
| 52-Week Low | 1.11 |
| Volume | 3.77M |
| Average Volume | 3.86M |
| Market Cap | 417.84M |
| PE | -1.89 |
| EPS | -0.83 |
| Moving Average 50 Days | 1.49 |
| Moving Average 200 Days | 1.74 |
| Change | 0.09 |
If you invested $1000 in Autolus Therapeutics plc (AUTL) since IPO date, it would be worth $62.6 as of December 04, 2025 at a share price of $1.565. Whereas If you bought $1000 worth of Autolus Therapeutics plc (AUTL) shares 5 years ago, it would be worth $149.05 as of December 04, 2025 at a share price of $1.565.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
GlobeNewswire Inc.
Nov 25, 2025 9:00 AM GMT
AUCATZYL® will be available through routine commissioning by the UK National Health Service (NHS)LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manu
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 13, 2025 9:05 PM GMT
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, annou